Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK crossover study of FP187 dimethyl fumarate formulations versus Tecfidera and Fumaderm in healthy volunteers
NL-OMON42556Phase 1Active, not recruiting
- Sponsor
- Forward Pharma
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of FP187-V2B, dimethyl fumarate and Fumaderm in psoriasis and multiple sclerosis (MS) (3 arms), sponsored by Forward Pharma. Primary endpoint: Pharmacokinetics of monomethyl fumarate after single-dose administration. Started Apr 2015; status: active, not recruiting.
02
Drugs
FP187-V2Bdimethyl fumarateFumaderm
03
Conditions
psoriasismultiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON42556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42556.